pivmecillinam (Selexid, Penomax, Coactabs)
Jump to navigation
Jump to search
Indications
- treatment of urinary tract infection (FDA-approved April 2024)[2]
- paratyphoid fever
- shigellosis
Contraindications
- carnitine deficiency
- other forms of inborn errors of metabolism
- methymalonic acidururia
- propionic aciduria
Dosage
Tablets: 185 mg
Pharmacokinetics
- pro-drug of mecillinam (active metabolite)
- other metabolites: pivalic acid
- oral bioavailability 25-35%
- protein bindng < 25%
- urinary excretion , primarily as mecillinam (80% of dose)
Antimicrobial activity
Adverse effects
More general terms
References
- ↑ Wikipedia: Pivmecillinam https://en.wikipedia.org/wiki/Pivmecillinam
- ↑ 2.0 2.1 Remally J FDA Approves New Antibiotic for Uncomplicated UTIs. Medscape. April 26, 2024 https://www.medscape.com/viewarticle/fda-approves-new-antibiotic-uncomplicated-utis-2024a100087g
FDA News Release. April 24, 2024 FDA Approves New Treatment for Uncomplicated Urinary Tract Infections. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections - ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION Pivya (pivmecillinam) tablet for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216483s000lbl.pdf